An Open-Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-F901318 Administered Via the Intravenous and Oral Routes to Healthy Male Subjects
Latest Information Update: 15 Mar 2021
At a glance
- Drugs Olorofim (Primary) ; Olorofim (Primary)
- Indications Coccidioidomycosis; Invasive bronchopulmonary aspergillosis; Mycoses
- Focus Pharmacokinetics
- Sponsors F2G
- 24 Jul 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 31 Jul 2018 Planned End Date changed from 1 Sep 2017 to 1 Jul 2019.
- 31 Jul 2018 Planned primary completion date changed from 1 Sep 2017 to 1 Jul 2019.